Tactile Systems Technology (NASDAQ:TCMD) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Tactile Systems Technology (NASDAQ:TCMD - Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Friday.

Separately, B. Riley cut Tactile Systems Technology from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $23.00 to $18.00 in a report on Wednesday, February 19th.

Tactile Systems Technology Price Performance

Shares of NASDAQ TCMD traded down $0.10 during trading on Friday, reaching $13.39. The company had a trading volume of 120,859 shares, compared to its average volume of 244,887. The company has a current ratio of 4.36, a quick ratio of 3.80 and a debt-to-equity ratio of 0.11. Tactile Systems Technology has a twelve month low of $11.12 and a twelve month high of $21.10. The stock has a 50-day moving average price of $15.73 and a two-hundred day moving average price of $15.82. The stock has a market capitalization of $315.80 million, a PE ratio of 19.13 and a beta of 1.24.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.09. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. The firm had revenue of $85.59 million during the quarter, compared to the consensus estimate of $85.39 million. As a group, sell-side analysts predict that Tactile Systems Technology will post 0.7 earnings per share for the current year.

Remove Ads

Insiders Place Their Bets

In other Tactile Systems Technology news, VP Kristie Burns sold 4,830 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $14.65, for a total transaction of $70,759.50. Following the completion of the sale, the vice president now owns 84,008 shares in the company, valued at $1,230,717.20. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel L. Reuvers sold 10,938 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $14.55, for a total value of $159,147.90. Following the completion of the transaction, the director now directly owns 242,942 shares in the company, valued at approximately $3,534,806.10. The trade was a 4.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,546 shares of company stock worth $285,444 over the last three months. 0.96% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in shares of Tactile Systems Technology during the fourth quarter worth about $2,793,000. Norges Bank acquired a new stake in shares of Tactile Systems Technology during the 4th quarter worth approximately $2,534,000. Renaissance Technologies LLC lifted its holdings in shares of Tactile Systems Technology by 44.0% in the 4th quarter. Renaissance Technologies LLC now owns 451,100 shares of the company's stock worth $7,727,000 after purchasing an additional 137,900 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in Tactile Systems Technology during the 4th quarter valued at approximately $1,328,000. Finally, Dimensional Fund Advisors LP grew its stake in Tactile Systems Technology by 8.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 901,551 shares of the company's stock worth $15,444,000 after buying an additional 67,934 shares during the last quarter. 83.43% of the stock is currently owned by institutional investors.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.